In a moment that extends the legacy of pandemic-era science into the rhythms of ordinary life, the FDA has approved Moderna's mFLUSIVA — the first mRNA-based influenza vaccine cleared for use in the United States — for adults 50 and older. The path to approval was neither smooth nor inevitable: regulators initially refused to review the application, only to reverse course after Moderna restructured its clinical strategy and committed to further study of older populations. That the approval came despite vocal opposition to mRNA technology from the very cabinet secretary who oversees the FDA spe
FDA Approves Moderna's mRNA Flu Vaccine After Regulatory Reversal
The FDA approved mRNA flu vaccine despite its own leadership's skepticism
Mark
Why did the FDA initially say no, then change its mind so quickly?
Mimi
The agency wanted to see how the vaccine compared to all the shots already recommended for older people, not just one. Moderna's trial was solid—40,000 people—but it didn't include the specific vaccine the FDA thought was most relevant for the 65-plus crowd. When Moderna agreed to run another study and split its approval request by age group, the FDA felt it had the evidence it needed.
Mark
Does Kennedy's opposition to mRNA technology actually matter here?
Mimi
It's the elephant in the room. Kennedy leads HHS, which oversees the FDA. The fact that the FDA approved this despite his public skepticism suggests the agency's scientists weren't willing to let politics override their judgment. But it also shows there's real tension at the top of the health department right now.
Mark
Is this vaccine actually better than what people already use?
Mimi
Better for some. The trial showed it outperformed one standard flu shot in adults over 50. But the FDA wanted to know how it stacked up against the vaccine specifically designed for older people. That's why they pushed back initially. Now Moderna has to prove itself in that head-to-head matchup.
Mark
What happens next?
Mimi
Moderna starts manufacturing for the 2026-27 flu season. The company will also be running that additional study on older adults. If that data looks good, the accelerated approval for 65-plus could become full approval. The real test is whether doctors and patients actually use it.
Il Polso
- The FDA's initial refusal to even open Moderna's application created a rare public standoff between a major vaccine maker and its regulator, raising questions about whether mRNA flu vaccines would face an impossible standard.
- At the center of the dispute was a 40,000-person trial that proved mFLUSIVA outperformed standard flu shots in adults over 50 — yet regulators argued the comparison was incomplete because it excluded a vaccine already recommended for those 65 and older.
- Moderna moved quickly to defuse the impasse, splitting its approval request by age group and pledging a dedicated study on older adults — concessions that brought the FDA back to the table within days.
- The approval now lands against a charged political backdrop, with HHS Secretary Robert F. Kennedy Jr. openly hostile to mRNA technology, making the FDA's green light a quiet but pointed assertion of regulatory independence.
- With doses expected in time for the 2026-27 flu season, the question shifts from whether mFLUSIVA could be approved to whether Americans 50 and older will choose it — and whether this milestone reshapes how the mRNA platform is perceived beyond Covid.
In a moment that extends the legacy of pandemic-era science into the rhythms of ordinary life, the FDA has approved Moderna's mFLUSIVA — the first mRNA-based influenza vaccine cleared for use in the United States — for adults 50 and older. The path to approval was neither smooth nor inevitable: regulators initially refused to review the application, only to reverse course after Moderna restructured its clinical strategy and committed to further study of older populations. That the approval came despite vocal opposition to mRNA technology from the very cabinet secretary who oversees the FDA speaks to the quiet persistence of scientific process within political weather.
On Wednesday, the FDA approved Moderna's mFLUSIVA, making it the first mRNA-based flu vaccine cleared for use in the United States. The shot is authorized for adults 50 and older, with doses expected in time for the 2026-27 flu season — a milestone Moderna described as validation of mRNA technology's potential well beyond the Covid vaccines that introduced it to the world.
The road to approval was unexpectedly turbulent. Earlier this year, the FDA refused to even open Moderna's application, citing problems with how the company had structured its clinical evidence. The core issue: a large trial had demonstrated mFLUSIVA outperformed standard flu shots in adults over 50, but FDA vaccine director Dr. Vinay Prasad argued the study failed to include a vaccine already recommended for those 65 and older, making the comparison insufficient.
Moderna responded by reworking its approach. The company sought full approval for adults aged 50 to 64 and accelerated approval for those 65 and older, while committing to an additional study focused on older populations. The FDA reversed its position within roughly a week, and approval followed.
The decision carries political weight. Robert F. Kennedy Jr., who leads the Department of Health and Human Services — the FDA's parent agency — has been a persistent critic of mRNA technology. That the FDA approved mFLUSIVA despite that pressure suggests the agency exercised independent scientific judgment. Whether the vaccine finds broad uptake among older Americans remains an open question, but the regulatory approval opens the door as flu season approaches.
On Wednesday, the Food and Drug Administration gave its blessing to Moderna's mFLUSIVA, marking the first time an mRNA-based flu vaccine has cleared the agency for use in the United States. The shot is approved for adults aged 50 and older, and the company expects to have doses ready for the 2026-27 flu season.
The approval represents a significant moment for mRNA technology as a platform beyond the Covid vaccines that made it famous. Moderna framed the decision as validation of the broader potential of its mRNA approach to address major public health problems through continued innovation. The company thanked clinical trial participants, investigators, regulators, and its own teams for making the milestone possible.
What makes this approval noteworthy is the path it took to get there. The FDA had initially refused to even review Moderna's application earlier this year, citing concerns about how the company had structured its clinical evidence. But within about a week, the agency reversed course. After discussions with Moderna about a revised regulatory strategy and an amended application, the FDA agreed to move forward with review.
The original dispute centered on a 40,000-person clinical trial that showed Moderna's vaccine worked better in adults over 50 than one of the standard flu shots currently available. Yet the FDA's vaccine director, Dr. Vinay Prasad, rejected the application in a refusal-to-file letter, arguing the trial had failed to include a specific vaccine brand that is already recommended for people 65 and older. The comparison, regulators felt, was incomplete.
Moderna responded by restructuring its request. The company now sought full approval for adults aged 50 to 64, while asking for accelerated approval for those 65 and older. It also committed to running an additional study focused specifically on how the vaccine performs in older adults. These concessions appear to have satisfied the FDA's concerns, and the approval followed.
The timing of this decision carries political weight. Robert F. Kennedy Jr., who leads the Department of Health and Human Services under the current administration, has been a vocal critic of mRNA technology. He has publicly opposed vaccines that use the platform. The FDA, which operates under HHS, approved mFLUSIVA despite this skepticism from its parent agency's leadership, suggesting the regulatory body maintained independence in its scientific judgment.
The approval signals that the FDA sees mRNA as a legitimate tool for addressing seasonal influenza, not merely a Covid-era experiment. Whether mFLUSIVA gains significant uptake among the 50-plus population remains to be seen, but the regulatory green light opens the door for Moderna to market the vaccine as flu season approaches in the fall of 2026.
Citazioni salienti
This approval reflects the ongoing potential of our mRNA platform to help address important public health challenges through continued scientific innovation— Moderna statement
Vuoi la storia completa?
Leggi l'originale su CBS News ↗
Health & Medicine